Lonza Netherlands, former PharmaCell Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Maastricht, Netherlands
Total Funding:N/A
Industry:Pharma
Founded:2005
Lead Investor(s):N/A
Press
Claim your profile

Industry Ranking

Estimated Revenue & Financials

  • Lonza Netherlands, former PharmaCell's estimated annual revenue is currently $47M per year.
  • Lonza Netherlands, former PharmaCell's estimated revenue per employee is $201,000

Employee Data

  • Lonza Netherlands, former PharmaCell has 234 Employees.
  • Lonza Netherlands, former PharmaCell grew their employee count by 35% last year.
  • Lonza Netherlands, former PharmaCell currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Dopharma B.V.
$27.7M13829%N/A
Lonza Netherlan...
$47M23435%N/A
Lygature
$10.5M5230%N/A
ACE Pharmaceuti...
$23.1M11511%N/A
Missing a competitor? Contribute!?
Submit

Lonza Netherlands is a Contract Manufacturing Organization (CMO) in the area of cell therapy and regenerative medicine (tissue culturing). The company works with European and US-based biotechnology companies on pre-clinical, clinical to commercial development projects and offers GMP and regulatory consultancy, cell culturing process development, fill and finish, Quality Control (QC)-testing and Good Manufacturing Practices (GMP) production services, as well as storage and distribution of clinical trial materials. PharmaCell is located in the center of Europe and operates two state-of-the-art cGMP-licensed facilities for human cell & tissue culturing in Maastricht and Geleen (Netherlands), conveniently located at approximately one hour driving distance from Brussels, Antwerp, Cologne and Dusseldorf.

keywords:N/A

234

Number of Employees

$47M

Revenue (est)

1

Current Jobs

35%

Employee Growth %

N/A

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Lonza Netherlands, former PharmaCell News

19-Jun-19 - Lonza building capacity for Gamida’s bone marrow transplant

Lonza will construct suites at its site in The Netherlands dedicated to producing ... did not divulge financial terms of the deal but old Bioprocess Insider his ... gene therapy network through the acquisition of PharmaCell in 2017.

9-Jun-17 - Lonza plugs EU cell and gene therapy gap through ...

The acquisition of Dutch commercial cell and gene therapy maker PharmaCell places Lonza as the leading CDMO in the space, the firm says.

1-Jun-17 - Lonza buys Dutch cell and gene therapy CMO

Visp, Switzerland-based Lonza has acquired Dutch gene and cell contract therapy manufacturer PharmaCell because of its expertise with ...